Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 4:54 AM
Ignite Modification Date:
2025-12-26 @ 3:55 AM
NCT ID:
NCT02879318
Group ID:
EG001
Title:
Gemcitabine + Nab-Paclitaxel + Durvalumab + Tremelimumab
Description:
Gemcitabine 1000 mg/m2 IV \& Nab-Paclitaxel 125 mg/m2 until unequivocal progression or unacceptable toxicity. Day 1, 8, 15 Q28 days.
plus Durvalumab 1500mg IV day 1 only Q28 days; and Tremelimumab 75 mg IV Days 1 cycles 1, 2, 3 and 4 only until unequivocal progression or unacceptable toxicity.
Gemcitabine
Nab-paclitaxel
Durvalumab
Tremelimumab
Deaths Number Affected:
102
Deaths Number At Risk:
None
Serious Number Affected:
82
Serious Number At Risk:
119
Other Number Affected:
118
Other Number At Risk:
119
Study:
NCT02879318
Results Section:
NCT02879318
Adverse Events Module:
NCT02879318